Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.36 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31236717 | 0.86 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1NQO1EGLN2SOS2 | |
| SCHEMBL7846050 | 0.77 | SOS2 (0.38) | ALDH1A1NQO1EGLN2SOS2KDM4E | |
| SCHEMBL701812 | 0.77 | NOS3 (0.44) | ALDH1A1NQO1EGLN2SOS2KDM4E | |
| SCHEMBL21928126 | 0.76 | NQO1 (0.39) | ALDH1A1NQO1EGLN2SOS2KDM4E | |
| SCHEMBL25268051 | 0.74 | KHK (0.36) | ALDH1A1NQO1EGLN2SOS2KDM4E | |
| SCHEMBL16372364 | 0.74 | SOS2 (0.48) | ALDH1A1NQO1EGLN2SOS2KDM4E | |
| SCHEMBL11916709 | 0.74 | SOS2 (0.36) | ALDH1A1L3MBTL1NQO1EGLN2SOS2 | |
| SCHEMBL2981097 | 0.74 | NQO1 (0.38) | ALDH1A1NQO1EGLN2SOS2KDM4E | |
| SCHEMBL16834623 | 0.74 | SOS2 (0.44) | ALDH1A1NQO1EGLN2SOS2KDM4E | |
| SCHEMBL29560656 | 0.74 | NQO1 (0.38) | ALDH1A1NQO1EGLN2SOS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| EP-3898646-B1 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4680611-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-01-21 | — | — | EP | disclosed |
| WO-2024189597-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-19 | — | — | WO | disclosed |
| US-20240309016-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-19 | — | — | US | disclosed |
| WO-2024009232-A1 | SUBSTITUTED N-(PYRIDIN-2-YL)ACETAMIDE DERIVATIVES AS CDK12/13 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-11 | — | — | WO | disclosed |
| US-20220372067-A1 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| WO-2020132504-A1 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10307414-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2172465-A1 | 2-(pyridin -2-yl)-pyrimidines and their use for controlling pathogenic fungi | BASF SE (DE) | 2010-04-07 | — | — | EP | disclosed |
| EP-2172466-A1 | 2-(pyridin-2-yl)-pyrimidines and use of same to combat hazardous fungi | BASF SE (DE) | 2010-04-07 | — | — | EP | disclosed |
| EP-2172467-A1 | 2-(pyridin -2-yl)-pyrimidines and their use for controlling pathogenic fungi | BASF SE (DE) | 2010-04-07 | — | — | EP | disclosed |
| EP-2163554-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-03-17 | — | — | EP | disclosed |
| EP-1773806-B1 | 2-(PYRIDIN-2-YL)-PYRIMIDINES AND THEIR USE FOR CONTROLLING PATHOGENIC FUNGI | BASF SE (DE) | 2010-02-24 | — | — | EP | disclosed |
| US-20080027085-A1 | 2-(Pyridin-2-Yl)-Pyrimidines and Their Use for Controlling Harmful Fungi | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-31 | — | — | US | disclosed |
| CN-1989125-A | 2-(pyridin-2-yl)-pyrimidines and their use for controlling pathogenic fungi | BASF AG (DE) | 2007-06-27 | — | — | CN | disclosed |
| EP-1773806-A1 | 2-(PYRIDIN-2-YL)-PYRIMIDINES AND THEIR USE FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010570-A1 | 2-(PYRIDIN-2-YL)-PYRIMIDINES AND THEIR USE FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372067-A1 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | HSD17B7, HSD3B1, HSD17B3 | ALDH1A1 651/4885L3MBTL1 3934/4885NQO1 1587/4885 |
| US-20080027085-A1 | 2-(Pyridin-2-Yl)-Pyrimidines and Their Use for Controlling Harmful Fungi | CBR1, CBR3, CNPY2 | ALDH1A1 1007/4885L3MBTL1 789/4885NQO1 448/4885 |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | ALDH1A1 407/4885L3MBTL1 2932/4885NQO1 959/4885 |
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | ALDH1A1 2160/4885L3MBTL1 2331/4885NQO1 1544/4885 |
| US-20240309016-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NTSR2 | ALDH1A1 2526/4885L3MBTL1 3574/4885NQO1 1483/4885 |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NPY1R | ALDH1A1 3220/4885L3MBTL1 857/4885NQO1 3918/4885 |
| US-10307414-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | BTK, LCK, TYK2 | ALDH1A1 2160/4885L3MBTL1 2331/4885NQO1 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.